Cytosorbents Corporation (CTSO)
After hours:
| Previous Close | 0.8410 |
| Open | 0.8400 |
| Bid | 0.8247 x 100 |
| Ask | 0.9298 x 100 |
| Day's Range | 0.8200 - 0.9000 |
| 52 Week Range | 0.7820 - 4.2900 |
| Volume | |
| Avg. Volume | 107,030 |
| Market Cap | 47.046M |
| Beta (5Y Monthly) | 0.62 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6400 |
| Earnings Date | Jul 30, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.63 |
Simply Wall St.Cytosorbents First Quarter 2024 Earnings: In Line With Expectations
Cytosorbents ( NASDAQ:CTSO ) First Quarter 2024 Results Key Financial Results Revenue: US$9.79m (up 3.6% from 1Q 2023...
Insider MonkeyCytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript
Cytosorbents Corporation (NASDAQ:CTSO) Q1 2024 Earnings Call Transcript May 9, 2024 Cytosorbents Corporation beats earnings expectations. Reported EPS is $-0.11717, expectations were $-0.12. Cytosorbents Corporation isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon and welcome to CytoSorbents’ First […]
GlobeNewswireCytoSorbents Reports First Quarter 2024 Results
Product Sales up a robust 14% over prior year, and a significant 22% sequentiallyWe believe the STAR-T data presented at AATS support a favorable benefit-to-risk profile of DrugSorb-ATR in coronary artery bypass graft (CABG) patients On track for U.S. Food and Drug Administration (FDA) De Novo and Health Canada submissions for DrugSorb®-ATR in Q3 2024 PRINCETON, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a pioneer in critical care and cardiac surgery blood pu
